Dude where’s my CAR-T? Personalised meds need personalised logistics, says TrakCel – BioPharma-Reporter.com
BioPharma-Reporter.com |
Dude where's my CAR–T? Personalised meds need personalised logistics, says TrakCel
BioPharma-Reporter.com The approval of Novartis' Kymriah (tisagenlecleucel) this week heralds a new era of personalised medicine, and – if Gilead's $11.9bn Kite investment pays off – soon two chimeric antigen receptor (CAR) T-cell therapies could be available in the US. |
